The Conversation (0)
VBL Therapeutics (Nasdaq:VBLT) today announces that it has received a milestone payment from NanoCarrier, (TSE Mothers:4571) in relation to the license agreement for the development, commercialization, and supply of ofranergene obadenovec in Japan. As quoted in the press release: “We are excited about reaching this important milestone with NanoCarrier, and for the continuing development of our access …
VBL Therapeutics (Nasdaq:VBLT) today announces that it has received a milestone payment from NanoCarrier, (TSE Mothers:4571) in relation to the license agreement for the development, commercialization, and supply of ofranergene obadenovec in Japan.
As quoted in the press release:
“We are excited about reaching this important milestone with NanoCarrier, and for the continuing development of our access to the Japanese market” said Dror Harats, M.D., chief executive officer of VBL Therapeutics. “Bringing this potentially life-changing new anticancer therapy to patients and physicians in Japan is important to all of us as we work to bring VB-111 to commercialization.”
